Pathogenic variants in TMEM184B cause a neurodevelopmental syndrome via alteration of metabolic signaling

Patient Inclusion

All research was performed in accordance with the Declaration of Helsinki. Most participants were identified by clinical sequencing and then unified via GeneMatcher.¹⁹ Subjects and their families agreed to allow de-identified information to be summarized from medical chart review and reported in this study. Subject 5 was also consented for fibroblast utilization and maintenance to a biorepository, which allows for residual samples from clinical procedures be collected, saved and distributed for research.

Genome Sequencing and Analysis

Sequencing was performed at each institution using either genome or exome approaches. Allele frequency was estimated using data from the gnomAD database (version 4.1.0) (https://gnomad.broadinstitute.org/) and was last queried in May 2024. Alphamissense was used to evaluate possible pathogenicity of each missense variant.²⁰ All analyses of sequence variation used transcript NM_001195071.1.

Structure Prediction

The native protein sequence was extracted from Uniprot, and each variant was inserted accordingly. Alphafold, along with MMSeq2, was employed to generate 3D structures of TMEM184B and its five clinically relevant missense variants. Structures were quality assessed via PLDDT and PAE scores, which provided five models for each protein structure. PLDDT gives the confidence score of the structure predicted (the higher, the better). Some loop regions that did not fit the desired criteria were truncated for cross-validation of the results. To assess the quality and reliability of the predicted protein geometry, the backbone dihedral angles of the predicted protein structures were mapped onto a Ramachandran plot. Similar to the PLDDT plot, we truncated the protein structure at the membrane to remove sequences in loops, a common practice in structural biology.²¹ Visualizations, including overlays of native and variant predicted protein structures, were created in Pymol 2.6. The best structure for native protein was chosen based on the highest PLDDT scores and the most favorable Ramachandran plot.

Zebrafish Husbandry and Embryo Maintenance

All experimental procedures were performed according to protocols approved by the Northwestern University Institutional Animal Care and Use Committee (IACUC; Protocol IS00016405). Wild type (WT) AB adults were maintained in standard husbandry conditions on a 14h light and 10h dark cycle. Embryos were obtained from natural matings with a 14 day rest period between each mating. Embryos were grown in egg water (0.3 g/L NaCl, 75 mg/L CaSO₄, 37.5 mg/L NaHC0₃, 0.003% methylene blue) at 28.5°C until phenotypic readout or tissue harvest.

Transient Depletion of tmem184ba

We obtained a morpholino (MO) to target the splice donor site of tmem184ba exon 6 (e6i6), (Gene Tools). tmem184ba was suppressed transiently by injecting 1 nl MO at increasing doses (1 ng, 2 ng and 3 ng) into one to four cell staged zebrafish embryos. To determine MO efficiency, we extracted total RNA from pools of 20 larvae/condition (controls and MO-injected) at 2 days post-fertilization (dpf) using Trizol (Thermo Fisher Scientific) according to manufacturer’s instructions. cDNA was synthesized with the QuantiTect Reverse Transcription kit (Qiagen). RT-PCR was performed using primers flanking the MO target locus, and amplified PCR products were separated on a 1% agarose gel. The resulting PCR bands were gel purified with the QIAquick gel extraction kit (Qiagen) and cloned into TOPO-TA cloning vector (Thermo Fisher Scientific). The purified plasmids from resulting colonies (n=4/PCR product) were sequenced using BigDye 3.1 terminator chemistry on an ABI3730 Genome Analyzer according to standard protocols.

Molecular Cloning, Site Directed Mutagenesis, and In Vitro Transcription of TMEM184B

To express human TMEM184B WT and variant mRNAs in zebrafish embryos, we obtained a Gateway-compatible WT TMEM184B (NM_012264.5; cat# HOC18517) open reading frame (ORF) entry vector (GeneCopoeia). We shuttled the ORF into a pCS2+ Gateway destination vector using LR clonase II (Thermo Fisher Scientific). The TMEM184B missense variants identified in affected individuals (V88M, L127R, G162R, K184E, and G288A; or a presumed benign negative control variant (R282H) dbSNP: rs370107940; 215 heterozygous and 4 homozygotes are present in 1609748 individuals in gnomAD v4.1.0) were introduced in the pCS2+ constructs using site-directed mutagenesis as described.²² After sequence verification of WT and variant ORFs, we linearized each construct with NotI and performed in vitro transcription with the mMessage mMachine SP6 Transcription kit (Thermo Fisher Scientific) according to manufacturer’s instructions. To test dominant effects, we injected 200 pg of each TMEM184B mRNA alone, and for a subset of variant mRNAs, titrated with WT in variable doses of 50 pg, 100 pg, and 150 pg while maintaining a total mRNA concentration of 200 pg. For in vivo complementation studies to test loss-of-function effects, we injected 200 pg mRNA with 3 ng MO.

Automated Live Imaging of Zebrafish Larvae

To assess head and body size, tricaine-anesthetized larvae were imaged at 3 dpf using the Vertebrate Automated Screening Technology (VAST) Bioimager (Union Biometrica) mounted to an AXIO Imager.M2m microscope (Zeiss) with a 10x objective lens. Larvae were passed sequentially through a 600 mm capillary on the stage module. Each larva was detected by VAST software (version 1.2.6.7) with a 40-70% minimum similarity and oriented automatically using preset recognition templates while operating in automatic imaging mode as described.²³ Bright field lateral and ventral images were captured with the VAST onboard camera.

Whole Mount Immunostaining

Larvae were reared to 3 dpf and fixed overnight in Dent’s solution (40% methanol [MeOH] plus 20% dimethyl sulfoxide [DMSO]). Embryos were then rehydrated gradually in MeOH, Phosphate-Buffered Saline (PBS) and 0.1% Tween (T) [PBST] at room temperature. We washed the embryos with bleach solution (9 mL PBST + 1 mL H₂O₂ + 0.05g KOH) for 13 minutes followed by proteinase K treatment for 10 minutes and fixed them in 4% paraformaldehyde (PFA) for 20 minutes at room temperature. Embryos were washed with PBST 3X (10 min each) and incubated in blocking solution (IF buffer [1% BSA in PBST] +10% fetal bovine serum [FBS]) for one to two hours. Primary detection was performed with anti-acetylated tubulin antibody (Sigma-Aldrich, T7451, 1:1,000 overnight at 4° C) and secondary detection with Alexa Fluor 488 goat anti-mouse IgG (Invitrogen; A11001, 1:1,000). Larvae were imaged by capturing fluorescent signal with an AZ100 microscope (Nikon) with a 10X objective mediated by Digital Sight black and white camera (Nikon) and NIS Elements software (Nikon).

Zebrafish Image Analysis

We used ImageJ (NIH) software to measure head and body size from lateral bright field images of zebrafish larvae using consistent anatomical landmarks. For fluorescence images, we measured size of the optic tecta and counted the number of commissural neurons that cross the midline on dorsal images.

Statistical Analysis of Zebrafish Morphometrics

All quantitative data were analyzed with an unpaired student’s t-test using GraphPad prism version 8. P-values <0.05 were considered statistically significant. Experiments were performed at least twice with investigator masked to injection conditions.

RT-PCR of TMEM184B

Fibroblasts were collected from Patient 5 under IRB-approved procedures. Fibroblasts were converted to induced pluripotent stem cells (iPSC) by the Washington University in St. Louis Genome Engineering and iPSC Center (GEiC). Control iPSC from an unaffected, sex-matched and approximately age-matched individual were purchased from Coriell Biobank (line GM23476). Cells were maintained in mTeSR media (StemCell Technologies) with antibiotics. RNA was isolated using the RNeasy Mini kit (Qiagen). Reverse transcription was performed using the Quanta Bio First Strand Synthesis kit, and PCR was done using Pfusion polymerase (New England Biolabs) according to product recommendations. Primer sequences were as follows: Forward (5’-TGTGTGGTGAAGCCACTCAT-3’) and Reverse (5’-ATAAGCCTTGCTCCCAGTGT-3’). Following gel isolation of PCR products, sequencing was submitted to Eton Biosciences (San Diego, CA). Alignments were performed in Snapgene.

Cell Culture and Reporter Cell Line Creation

HEK293T cell lines were cultured in 1X Dulbecco’s Modified Eagle Medium (Ref#11995-065) supplemented with 10% FBS, L-glutamine, and 1X Penicillin Streptomycin at 37°C and 5% CO2. To create stable cell lines expressing both TFEB-sfGFP and H2B-mRuby, infection and selection were done sequentially. First, retrovirus expressing TFEB-sfGFP (Addgene Plasmid #135402) was produced by transfecting HEK293T cells with TFEB-GFP plasmid, pVSV-G, and pMD2.G with GeneJuice (Millipore Sigma) and Optimem (Gibco). HEK293T cells were infected with TFEB-sfGFP retrovirus along with polybrene (8ug/mL). A population with high green fluorescence levels was isolated via flow cytometry (BD FACSAria III). TFEB-sfGFP expressing cells were then infected with H2B-mRuby lentivirus (Addgene Plasmid #90236) prepared as above except that VSV-G was replaced with PSPAX2. A population with high TFEB-sfGFP and H2B-mRuby were isolated using FACS and were further selected via sequential treatment with 8 μg/mL puromycin and 400 μg/mL hygromycin.

TFEB Translocation Assay

FL-TMEM184B-miRFP670 plasmid constructs were ordered from Twist Bioscience. Plasmid purity and quantity was assessed via Nanodrop (260/280 ratio > 1.9). On Day 0, TFEB-sfGFP/ H2B-mRuby stable cells were transiently transfected with TMEM184B constructs using GeneJuice. On Day 1, each condition was seeded in duplicate into 96-well black bottom plates and transferred to the University of Arizona’s Microscope Shared Resource facility and left overnight in 37°C and 5% CO2. On Day 2, media was changed to phenol red-free imaging media. Dulbecco’s Modified Eagle Medium (Ref#21063-029) was supplemented with 10% FBS, L-glutamine, 1X Penicillin Streptomycin, and 110 ng/L sodium pyruvate and applied to one duplicate (complete media, non-starved), and Dulbecco’s Modified Eagle Medium (Ref#A14430-01) was supplemented with only 1X Penicillin Streptomycin for the other duplicate (starved).

The University of Arizona Microscopy Shared Resource facility’s Nikon SoRa spinning-disk confocal microscope was used for imaging. Cells were imaged at 37°C and 5% CO2 in a 4x4 grid with 8% overlap from the center of the well every hour for 6 hours. 20x magnification, 4x4 binning, and 16-bit parameters were used. sfGFP, mRuby, and miRFP670 fluorescent channels were captured.

Image Analysis

A rolling ball background subtraction of 29.86 μm was applied to the sfGFP channel in Nikon NIS Elements software post-acquisition. Individual frames were then exported and analyzed using QuPath imaging pipelines. Cell nuclei were defined by the H2B-mRuby channel and were expanded 2 μm outwards to define the perinuclear region. Detections were filtered through thresholding for nuclear circularity, nuclear area, cell area, GFP intensity, cell circularity, and miRFP670 intensity.

Nuclear to perinuclear sfGFP fluorescence ratios were quantified in non-starved cells, and cells starved at 1-hour and 6-hour timepoints. All conditions were normalized to non-starved HEK293T cells expressing WT TMEM184B. GraphPad Prism 10 was used for statistical analysis. Data normality was assessed using Shapiro-Wilk tests. Nonparametric One-Way ANOVA tests with adjusted p-values were calculated in Graphpad Prism 10, comparing each condition to WT at each timepoint.

Zombie-Violet cell death assay

HEK293T cells were transfected with TMEM184B-miRFP670 containing native sequence or patient variants and cultured for 2 days. Prior to Zombie-Violet assay, cells were starved by incubating with Dulbecco’s Modified Eagle Medium (Ref#A14430-01) at 37°C and 5% CO2 for 6 hours. Cell incubation was according to the manufacturer’s protocol (BioLegend).

Zombie-Violet was diluted 1:500 in DPBS and 100 μL of solution were used per one million cells. Cells were washed with 0.5% BSA/PBS, fixed in 2% PFA, washed once with DPBS, and transferred to the University of Arizona’s Flow Cytometry Core to be analyzed (BD FACSCanto II). FlowJo software was used for FACS analysis, and GraphPad Prism 10 was used to create graphs of cell percentages and perform statistical testing (One-Way Parametric ANOVA).

De Novo Heterozygous Disruptions in Human TMEM184B Cause Neurodevelopmental Defects

We leveraged the GeneMatcher platform to identify TMEM184B variants that may be disease-causing. We identified six affected individuals in which exome or genome sequencing (ES or GS, respectively) identified a rare mRNA splice site or amino acid disruption to TMEM184B. Subjects and their families agreed to allow de-identified information to be summarized and published in this manuscript. For these patients, we obtained information from physicians and genetic counselors about the alteration in the DNA sequence and the clinical findings observed (Table 1 and Supplementary Files 1 and 2). In this dataset, all six affected individuals were diagnosed with neurodevelopmental deficits as children and then, by sequencing, were found to carry a variant of unknown significance (VUS) in the TMEM184B locus.

All six patients show phenotypic overlap. Patient symptoms coalesce around a few major clinical findings: developmental delay (5 of 6), corpus callosum hypoplasia (4 of 6, Figure 1) or more severe structural disruption resulting in microcephaly (1 of 6), seizures (3 of 6), and intellectual disability (2 of 6). Other non-neurological features are also present in some patients (Supplemental File 2). While two patients showed variants of unknown significance (VUS) outside the TMEM184B locus, ES or GS of the remaining four patients did not identify other possible genetic contributors to their clinical sequelae. The similarity in presentation across the case series is consistent with a potential causal role for the TMEM184B variants in these symptoms. Of note, while our study was ongoing, the V88M variant was reported in gnomAD to be present at a low frequency in the general population (Table 1). All missense variants in our study are predicted to be highly damaging to conserved protein structural features, as determined using AlphaMissense (Table 1).²⁰

• Download figure
• Open in new tab

Figure 1: Brain magnetic resonance imaging (MRI) shows corpus callosum hypoplasia in two patients with TMEM184B variants.

A Sagittal plane of spoiled gradient recalled acquisition (SPGR) MRI in a patient of the same age as patient 5 who has an unrelated gene variant and shows no alterations in corpus callosum thickness. B Sagittal T2 MRI in patient 4 (K184E) shows corpus callosum disruption. C Sagittal SPGR MRI in patient 5 (c.589+1 G>A) shows corpus callosum hypoplasia.

Human Variants are Predicted to Alter Structure and Stability of TMEM184B Protein

The TMEM184B locus is predicted to be transcribed in two major isoforms, with variant “a” (NM_001195071.1) representing the full sequence. By mapping patient variants onto the linear mRNA, we found that variants cluster in portions of the gene that encode the transmembrane (TM) regions or the loop region between TM3 and TM4 (which is predicted to be cytoplasmic) (Figure 2A). We note that the variants within membrane-spanning helices correspond to the most severe patient presentations, suggesting that these changes might be severely disruptive to protein function. The 3D structure of the native protein was predicted using AlphaFold, and the best model was selected based on the PLDDT scores and Ramachandran plot (Figure 2B-D). The Ramachandran plot shows the backbone dihedral angles in permitted regions, suggesting a high-quality structure. Figure 2D shows the transmembrane portions of TMEM184B predicted by this model, highlighting the 7 transmembrane domains found in the structure. We then built variants into this model and visualized their effects on the predicted structure (Figure 2E-F). Variants V88M and K184E show major disruptions to their transmembrane regions, with large shifts apparent both from top and side views.

• Download figure
• Open in new tab

Figure 2. Structural modeling and free energy of TMEM184B variants indicates significant disruptions to protein stability.

A Structure of the human TMEM184B transcript (NM_001195071.1). Blue and gray blocks show alternating exons of the spliced mRNA. Red arrow indicates the coding region of isoform a (NP_001182000.1). Areas predicted to be included in transmembrane helices (green) and locations of human variants (black) are noted. B Ramachandran plot showing that the structure predicted by FoldX analysis shows only allowable angles, providing confidence in the structure predicted. C Predicted local-distance difference test (pLDDT) scores per position across the whole protein sequence. Higher scores indicate higher confidence structural predictions in that region of the protein. D Native protein structure prediction by FoldX. Transmembrane helices are separately colorized. E V88M variant protein (magenta) overlaid onto the native TMEM184B structure (cyan). F K184E variant protein (green) overlaid onto the native TMEM184B structure (cyan). G Stability analysis calculations using Gibbs free energy. ΔΔG values that are positive indicate decreased protein stability of variant-containing TMEM184B when compared to the predicted native structure, while negative values indicate abnormally heightened protein structural stability. H Amino acid context for the V88M and K184E variants, both of which are conserved from yeast (Saccaromyces cerevisciae Hfl1) to humans. All other variants are conserved from Drosophila (Tmep) to human but are not found in yeast.

We undertook a quantitative analysis of protein structural stability of human TMEM184B using FoldX. The 3-D structures were used as input data for the Mac version of FoldX 5.0 to predict their ΔG. The stability of the protein structures was predicted using FoldX, where the native protein and each variant (G162R, G288A, K184E, L127R, V88M) underwent a stability analysis to calculate their respective total energies. We also performed this analysis for a commonly occurring TMEM184B sequence variant, R282H, as a comparison. The change in Gibbs free energy (ΔΔG) was then determined for each variant relative to the native structure to assess the impact of the mutations on protein stability. Variants with large positive ΔΔG values were associated with destabilizing variants, potentially leading to loss of function, while negative ΔΔG values suggested stabilizing mutations that could result in gain of function or dominant negative effects (Figure 2G). The common variant R282H showed a small shift in ΔΔG, consistent with it being presumed benign. We also analyzed the evolutionary conservation of the specific amino acids altered in patients with neurodevelopmental defects. All amino acid locations show conservation throughout vertebrate and invertebrate animals; remarkably, V88 and K184 are also conserved in the yeast ortholog, Hfl1 (Figure 2H). Overall, this analysis provides insight into the potential disruptive effects of the identified patient variants.

The Zebrafish Ortholog of TMEM184B is Involved in Zebrafish Development

We and others have shown previously that zebrafish are a robust vertebrate developmental model that can inform not only physiological relevance to neurodevelopmental disease, but also variant effect. To test these possibilities, first we identified the zebrafish TMEM184B ortholog using reciprocal BLAST searches between the human TMEM184B protein, GenBank ID: NP_001182000.1, and the translated zebrafish genome. This query identified two zebrafish orthologs: tmem184ba, ENSDARG00000045147; 82% similarity, 80% identity and tmem184bb, ENSDARG00000090876; 77% similarity, 74% identity, versus human protein, respectively. Next, we used database and literature searches to find that expression of tmem184ba is markedly higher in whole larvae during the first five days of development than tmem184bb ²⁴, and that tmem184ba has a ∼23-fold higher expression level in the zebrafish head at 3 dpf than its paralog.²⁵ Thus, we reasoned that tmem184ba is the most relevant ortholog of TMEM184B, and that its spatiotemporal expression in the zebrafish head supported a potential physiological role in neurodevelopment.

To bolster a possible role for tmem184ba in formation and function of neural structures, we transiently suppressed its expression with a morpholino (MO) targeting the exon 6 splice donor site (Supplementary File 3A). Monitoring of mRNA splicing events in MO-injected larvae with RT-PCR and sequencing of cloned PCR products showed exon 6 exclusion, which removed 92 bp and resulted in a putative premature termination (Supplementary File 3B, C). Next, we showed that injection of increasing doses of MO (1 ng, 2 ng, and 3 ng) into WT embryos resulted in a dose-dependent reduction in head size and body length in larvae subjected to automated live bright field imaging at 3 dpf, with the highest dose producing a ∼10% reduction in head area (Supplementary File 3D, E, F), supporting a role for TMEM184B in overall animal growth.

TMEM184B is Involved in Neurodevelopment and De Novo Missense Variants Confer Dominant Toxic or Loss of Function Effects

Given that all variants in our cohort are heterozygous de novo changes, we hypothesized possible molecular mechanisms of dominant toxicity or haploinsufficiency. We and others have shown previously that ectopic expression of human mRNA in zebrafish larvae followed by quantitative phenotyping can inform dominant effects such as dominant negative (variant interacts with WT to produce a phenotype)²⁶ or dominant toxic (variant gains a new function that is deleterious independent of endogenous WT).^27–29 We used an established paradigm ²² to test for dominant effects by injecting a fixed dose (200 pg) of human TMEM184B WT and variant mRNA (V88M, L127R, G162R, K184E and G288A) in WT zebrafish embryos at the one to four cell stage and quantified the head and body size at 3 dpf as proxies for neurodevelopmental and growth deficits of affected humans. In replicate experiments, WT mRNA did not result in any detectable phenotypes compared to controls, but we observed a significant reduction in head size with concomitant reduction in body length for G162R and K184E larvae injected with an equivalent mRNA dose suggesting a dominant effect (Figure 3A, B, C). By contrast, overexpression of V88M, L127R, G288A, or R282H, the presumed benign variant, did not result in any detectable alteration of anterior structures or overall animal size (Figure 3D, E). Together, these data indicated divergent variant effects.

• Download figure
• Open in new tab

Figure 3. Ectopic expression of TMEM184B variants G162R or K184E induces head size and body length phenotypes in zebrafish larvae.

A Representative bright field lateral images of 3 day post-fertilization (dpf) larvae injected with 200 pg human TMEM184B mRNA (WT, G162R, K184E and R282H). R282H is a presumed benign negative control (dbSNP: rs370107940; 215 heterozygotes and 4 homozygotes are present in 1609748 individuals in gnomAD v4.1.0. Scale bar, 300 μm. Head area was measured according to white dashed line; body length was measured according to the red dashed line. B and C Quantification of the lateral head size in 3 dpf larvae. Experimental conditions were normalized and presented as a percentage of the control mean. D and E Quantification of the body length in 3 dpf larvae. Experimental conditions were normalized and presented as a percentage of the control mean. Statistical analyses were performed with an unpaired student’s t-test; ∗∗∗∗p<0.0001; ∗∗∗p<0.001; and ns, not significant; n = 50–87/condition. Error bars represent standard deviation of the mean. Data point color: black, uninjected control; blue, WT; red, variants identified in affected individuals; green, presumed benign variant from gnomAD.

To dissect further the possibility of dominant negative or dominant toxic (WT dependent versus independent variant effect, respectively), we co-injected embryos with progressively decreasing WT mRNA doses with progressively increasing variant mRNA doses while maintaining the overall human transcript amount constant (200 pg). Using the same phenotyping measures at 3 dpf, we found that for both G162R and K184E all three conditions injected with WT plus variant mRNA resulted in altered head size phenotypes but their effect was not significantly different from 200 pg WT mRNA, indicative of a dominant toxic effect (Figure 4 A and C). For body length measurements, we observed significant differences for WT-variant mRNA combinations versus 200 pg variant mRNA alone, but there was no consistent dose-dependent effect that could indicate a dominant negative effect (Figure 4 B and D). Although our in vivo data could not resolve the precise molecular mechanism of variant action, they suggested that G162R and K184E likely confer pathogenic effects through WT-independent biochemical mechanisms.

• Download figure
• Open in new tab

Figure 4. Titration of G162R or K184E mRNAs with WT TMEM184B mRNA to dissect dominant negative or dominant toxic effects.

A and B Quantification of the lateral head size in 3 dpf larvae injected with titrated doses of WT with variant mRNA. Experimental conditions were normalized and presented as a percentage of the control mean. See Figure 1A for anatomical landmarks measured. C and D Quantification of the body length in 3 dpf larvae injected with titrated doses of WT with variant mRNA. Experimental conditions were normalized and presented as a percentage of the control mean.

See Figure 1A for anatomical landmarks measured. Statistical analyses were performed with an unpaired student’s t-test; ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05; and ns, not significant; n = 49–72/condition. Error bars represent standard deviation of the mean. Data point color: black, uninjected control; blue, WT; red, variants identified in affected individuals. Large triangles indicate decreasing or increasing amounts of WT (blue) or variant (red) mRNA.

Next, we pursued a loss of function hypothesis for V88M, L127R, and G288A by employing a complementation strategy, which compares rescue ability of human WT versus variant TMEM184B mRNA in the presence of MO.²² First, we established experimental parameters in which co-injection of WT mRNA restored larval head and body length phenotypes to measurements indistinguishable from controls (Figure 5A, B, C). Next, we compared the rescue of each variant mRNA to either MO alone or WT mRNA; we observed that each of V88M, L127R and G288A rescue both head size and body length phenotypes significantly worse than the WT or the negative control variant, R282H (Figure 5A, B, C). These data indicate that these three disease-associated variants confer reduced protein function consistent with a haploinsufficiency basis for disease.

• Download figure
• Open in new tab

Figure 5. Loss of tmem184ba results in neuroanatomical defects and in vivo complementation shows that some disease associated variants result in loss of function.

A Representative bright field lateral images of 3 dpf larvae injected with MO with or without human TMEM184B mRNA (WT, V88M, L127R, G288A and R282H). R282H is a presumed benign negative control (dbSNP: rs370107940; 215 heterozygotes and 4 homozygotes are present in 1609748 individuals in gnomAD v4.1.0. Scale bar, 300 μm. Head area was measured according to anatomical landmarks shown in Figure 1A. B Quantification of the lateral head size in 3 dpf larvae as indicated with anatomical landmarks in Figure 1A. Experimental conditions were normalized and presented as a percentage of the control mean. C Quantification of the body length in 3 dpf larvae as indicated with anatomical landmarks in Figure 1A. Experimental conditions were normalized and presented as a percentage of the control mean. For panels B and C, n = 50–88/condition. D Representative dorsal images of 3 dpf larval heads painted with acetylated tubulin. White dotted shape, optic tecta; white dotted line, midline between optic tecta where intertectal commissural axons were counted. Zoomed image at right of each panel corresponds to white box around both optic tecta. Anterior, left; posterior, right; Scale bar, 50 μm. E Quantification of optic tecta size as shown in panel D. F Quantification of intertectal neurons that cross the dorsal midline as shown in panel E. For panels E and F, n = 30– 47/condition. For panels B, C, E and F, statistical analyses were performed with an unpaired student’s t-test; ****p<0.0001; ***p<0.001; **p<0.01, *p<0.05, and ns, not significant. Error bars represent standard deviation of the mean. Data point color: black, uninjected control; blue, WT; red, variants identified in affected individuals; green, presumed benign variant from gnomAD.

To achieve further resolution into the neuroanatomical phenotypes induced by tmem184ba impairment, we performed whole mount staining of 3 dpf zebrafish larvae with acetylated tubulin to demarcate optic tecta and intertectal neurons, established proxies for microcephaly and corpus callosum defects in humans.^30,31 In biological triplicate experiments, we observed a significant reduction in optic tecta size for morphants compared to controls, a phenotype that could be rescued significantly by co-injection of WT human mRNA (Figure 5D, E). Additionally, we counted the number of neuronal axon tracts crossing the dorsal midline and found a significant reduction in morphants, which could also be rescued by co-injection of WT human TMEM184B (Fig 5D, F). These data show discrete neuroanatomical features impaired by tmem184ba depletion beyond overall head and animal body growth, and further demonstrate reagent specificity with rescue of MO-induced phenotypes with WT human mRNA.

TMEM184B Variants Affect Protein Expression Levels and Cell Viability

To analyze further the cellular consequences of disease-linked TMEM184B variants, we modeled their effects by over-expression in a human cell line (HEK293T). Using this model, we hypothesized that dominant effects of patient variants would be detectable. We created mi670-tagged expression constructs of human TMEM184B, containing either the WT form or a variant matching one of the six disease-associated variants. To determine how to model patient 5 (splice acceptor change), we used RT-PCR to amplify and then sequence the area surrounding the variant in induced pluripotent stem cells derived from this affected individual. We identified two primary amplicons, one of which was found to be the canonical sequence. The smaller amplicon showed a complete deletion of exon 7 (Supplementary File 4). While other minor species may not have been detected by this analysis, our data suggest that exon 7 deletion (Ex7del) is the primary effect of the IVS8+1G>A variant. Therefore, one of our expression constructs was built to model this deletion. The protein product of an exon 7 deletion is a nonsense variant that removes transmembrane helices 5-6 and terminates the protein shortly thereafter.

Microcephaly could be caused by reduced proliferation of neural progenitors, or by reduced viability of variant-expressing cells in the brain.^32,33 To examine viability of cells expressing patient variants of TMEM184B, we analyzed apoptosis in human cells transiently transfected with each of the six TMEM184B variants. Given the differences in structural stability between variants, we first compared the expression levels of fluorescently tagged versions of all variants to the WT protein expression. This analysis showed that, with one exception (G162R), all patient variant proteins show reduced overall levels compared to WT (Figure 6A-C and Supplemental File 5). We have not determined if this is due to nonsense mediated decay of mRNA or to increased degradation of a structurally compromised protein. However, in either case, our data predict that variant proteins are not present in cells at the same level as the WT protein.

• Download figure
• Open in new tab

Figure 6. TMEM184B variants affect protein expression levels and cell viability

A and B Histogram of miRFP670 fluorescence indicating expression levels of WT vs. (A) K184E or (B) V88M variants. C Average fluorescence of TMEM184B variants normalized to WT (N=3 trials). Error bars represent SEM. D FACS plots of HEK293T cells over-expressing native TMEM184B (top row) or K184E variant (bottom row) under non-starved or 6 hour-starved conditions. Numbers indicate the percentage of dead cells among non-transfected HEK293T cells (left, calculated by dividing top left cell count by overall untransfected cell count left of the white line) or TMEM184B-transfected HEK293T cells (right, calculated by dividing top right cell count by overall transfected cell count right of the white line). E Percentage of dead TMEM184B variant expressing cells normalized to WT (N=3 trials). In panels C and E, error bars represent SEM. ****p<0.0001, **p<0.01.

We then analyzed apoptosis using a flow cytometry assay based on accumulation of Zombie Violet, an amine-reactive dye, in dead cells. In normal media, cells overexpressing K184E, Ex7del, and G288A showed increases in cell death of 2-7x compared to cells overexpressing the WT TMEM184B protein (Figure 6D-E and Supplemental File 6). For K184E and Ex7del, this increase in cell death continued after starvation (Supplementary Figure 5K).

Variant Expression Disrupts Shuttling of the Lysosomal Biogenesis Transcription Factor EB (TFEB)

Signaling pathways that operate downstream of TMEM184B are unknown, but prior work suggests an intersection between these pathways and the processes of synaptic growth, proliferation, and autophagy.^1,2,7 In cells starved of nutrients, transcription factor EB (TFEB) is dephosphorylated and enters the nucleus to transcribe lysosomal and autophagosomal genes to promote recovery from metabolic stress.¹⁶ Knockdown of TMEM184B expression in cell lines alters its starvation-induced distribution, causing prolonged nuclear retention TFEB.³⁴ We therefore postulated that patient variants might also alter the nuclear-to-cytoplasmic distribution of TFEB. We generated HEK293T cell lines stably expressing TFEB-GFP and H2B-mRuby (nuclear marker), and analyzed the Nuclear:Cytoplasmic ratio of TFEB-GFP in the presence of each TMEM184B patient variant. Strikingly, we found that in normal (unstarved) conditions there were already significant differences in TFEB distribution in the presence of many TMEM184B variants. The variants split into two groups: K184E, Ex7del, and G288A increased the nuclear:cytoplasmic ratio of TFEB, while V88M decreased the ratio (Figure 7). TFEB localization varied across all patient variants for six hours, with all of them displaying significant differences in at least one time point (Figure 7M-N, Supplemental File 7).

• Download figure
• Open in new tab

Figure 7. TFEB nuclear-to-cytoplasmic ratio is dominantly altered by expression of patient TMEM184B variants.

A-D and G-J Multichannel images of non-starved HEK293T cells overexpressing WT or K184E, respectively. TFEB-GFP (A and G), H2B-mRuby (B and H), TMEM184B-miRFP6670 (C and I), and merge (D and J). E-F and K-L are WT and K184E cells starved for one hour, respectively. TFEB-GFP (E and K) and merge (F and L). Arrows in all images point to TMEM184B-miRFP670 transfected cells. All H2B-mRuby images had their Lookup Tables adjusted to 4000 for visual clarity. M Ratio of mean TFEB-GFP fluorescence in the nucleus vs. cytoplasm in TMEM184B-miRFP670 expressing cells, normalized to non-starved WT cells. N Timelapse of TFEB localization (nucleus vs. cytoplasm) of K184E and IVS8+1G>A (exon 7 deletion) expressing cells at baseline, one hour, and six hour starvation timepoints (N=3 trials). M and N error bars represent SEM. ****p<0.0001, *p<0.01. 50 cells were quantified in every trial for every patient variant and time point except for K184E at six hour starvation (42-50 cells) and Ex7del at all time points. At no starvation, one hour, and six hours, we quantified between 43-50, 42-50, and 14-42 cells respectively.

To identify concordance between our zebrafish and cellular findings with patient phenotypes, we provide a table aligning clinical features and important discoveries from our models (Table 2).